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Background
PFAPA is characterized by periodic fever, aphthous stoma-
titis, pharyngitis and cervical adenitis. Children are
healthy between fever atacks. First manifestation is usu-
ally before 5 years of age. The ethiopathogenesis is
unknown. There are few diagnostic criteria which help to
make the clinical diagnosis. Laboratory parameters are
non – specific.
Methods
Retrospective case analysis.
Results
Over the years 2004 – 2007 17 boys and 15 girls were
diagnosed with PFAPA out of 87 patients referred to the
fever clinic (36.8%). Median age at onset was 24 months
(4–56), interval between attacks 4 weeks (2–12) and fever
duration 3.5 days (1.5–7). Fever was generally above
39°C, associated with pharyngitis in 23 cases (71.9%),
cervical adenitis in 24 (75%) and aphthous stomatitis in
11 (34.4%). Other symptoms: abdominal pain, arthralgia
(each in 7 cases), vomiting and headache (each in 4
cases). All children had elevated inflammatory parameters
during attack (median: CRP 64.5 g/l, ESR 32/h) with sub-
sequent normalization. The single prednisone dose of 1
mg/kg administered at the onset of an episode helped to
reduce symptoms in 16/18 children. In 2 cases tonsillec-
tomy led to the resolution of symptoms. After the median
follow-up of 8.7 months (3.1–35.5) 4/32 patients
(12.5%) have been in the full remission.
Conclusion
PFAPA appears to be a relatively common cause of recur-
rent fever in early childhood. The diagnosis was made
after clinical exclusion of hereditary fevers and other sys-
temic diseases or immune deficiencies. Our current diag-
nostic algorithm, therapy and follow-up scheme need
further prospective evaluation.
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